Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$888.03 USD

888.03
330,178

+3.55 (0.40%)

Updated Oct 2, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Johnson & Johnson Files sNDA for Label Expansion of Invokana

by Zacks Equity Research

Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

    Lilly (LLY) Makes Leadership Changes to Executive Positions

    by Zacks Equity Research

    Eli Lilly and Company (LLY) makes some executive appointments for various departments.

      Radius (RDUS) Enrols First Patient in Breast Cancer Study

      by Zacks Equity Research

      Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.

        Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

        by Zacks Equity Research

        Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

          Madeleine Johnson headshot

          Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why

          by Madeleine Johnson

          On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.

            Arpita Dutt headshot

            3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

            by Arpita Dutt

            With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

              J&J's Arthritis Candidate Sirukumab Denied FDA Approval

              by Zacks Equity Research

              J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                Arpita Dutt headshot

                Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs

                by Arpita Dutt

                Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.

                  Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer

                  by Zacks Equity Research

                  Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.

                    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

                    by Zacks Equity Research

                    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

                      Arpita Dutt headshot

                      Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

                      by Arpita Dutt

                      Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

                        4 Biotech Stocks That Show Promise on Sustainable Growth

                        by Zacks Equity Research

                        Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

                          Array's NDAs for Melanoma Combo Accepted for Review by FDA

                          by Zacks Equity Research

                          Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

                            AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                            by Zacks Equity Research

                            AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                              Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth

                              by Zacks Equity Research

                              Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018

                                by Arpita Dutt

                                Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.

                                  Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer

                                  by Zacks Equity Research

                                  Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.

                                    Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018

                                    by Zacks Equity Research

                                    Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update

                                      by Arpita Dutt

                                      It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis' (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States.

                                        Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected

                                        by Zacks Equity Research

                                        Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.

                                          Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%

                                          by Zacks Equity Research

                                          Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.

                                            Biogen Alzheimer's Drug Shows Promise in Long-Term Study

                                            by Zacks Equity Research

                                            Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.

                                              Anthera's Blisibimod Positive in Phase II Extension Study

                                              by Zacks Equity Research

                                              Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.

                                                Novo Nordisk's Victoza Gets FDA Nod for Label Expansion

                                                by Zacks Equity Research

                                                Novo Nordisk's (NVO) Victoza receives FDA nod for its label expansion to include cardiovascular events in adult patients with type II diabetes. Shares up.

                                                  Zoetis (ZTS) Poised to Grow on Companion Animal Portfolio

                                                  by Zacks Equity Research

                                                  Zoetis, Inc. (ZTS) expects to witness stronger growth from its companion animal portfolio in 2017 driven by its dermatology portfolio, Apoquel and Cytopoint, further penetration of Simparica,